Arcutis Biotherapeutics (ARQT) Q2 FY26 earnings call

Arcutis Biotherapeutics delivered a strong second quarter, driven by robust demand for its ZORYVE franchise and strategic investments in commercial expansion and patient access initiatives. The company raised its full-year sales guidance, reflecting sustained momentum and the anticipated impact of new virtual health and AI-enabled prescription workflow platforms. Pipeline progress continues with key clinical trials advancing, reinforcing the company's commitment to innovation in chronic inflammatory skin diseases.